Skip to content

Sanoculis Ltd.

Israeli ophthalmic medical device company developing the MINT® minimally invasive glaucoma surgery system.

Last updated September 29, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Sanoculis Ltd. is an Israeli ophthalmic medical device company based in Kiryat Ono. The company specializes in minimally invasive glaucoma surgery (MIGS) technology and has developed a proprietary, stentless surgical approach designed for performing sclerostomy and trabeculostomy during glaucoma angle surgeries. Its flagship offering is the MINT® (Minimally Invasive Nasal Trabeculostomy) surgical device and procedure. The MINT® system is designed to create five drainage pathways directly within the trabecular meshwork. These pathways are intended to form openings in the trabecular meshwork tissue, facilitating the flow of fluid from the anterior chamber to Schlemm's Canal. The procedure can be performed either as a standalone treatment or in conjunction with cataract surgery. According to the company, post-operative complications following MINT® surgery are expected to be minimal and at a lower incidence. The MINT® procedure uses a unique mechanical semi-automated trephination with a cutting edge diameter of 0.14 mm. The procedure involves four main steps: preparation (making a corneal incision, injecting OVD, and inserting the MINT® surgical device into the anterior chamber), positioning the device tip on the pigmented functional trabeculum band using a gonioscope, pressing the pedal to create a trabeculostomy opening in the pigmented trabecular meshwork, and performing four additional openings at different sites in the nasal pigmented functional trabecular meshwork. Sanoculis has reported clinical results for MINT® standalone use. At two years, the company reported 97.2% qualified success (N=35/36) and 69.4% complete success (N=25/36), using the FDA definition of success: a 20% or more reduction from baseline in mean intraocular pressure (IOP) without increasing the number of glaucoma medications. Year 1 results were reported as 92.9% qualified success (N=52/56) and 78.6% complete success (N=44/56). The company's mission, as stated on its website, is to deliver innovative solutions in glaucoma surgery. Sanoculis operates in the global ophthalmic medical device market, focusing on glaucoma treatment. The company is privately held and headquartered in Kiryat Ono, Israel.

History

Sanoculis Ltd. is an Israeli medical device company headquartered in Kiryat Ono. The company was founded to develop minimally invasive solutions for glaucoma surgery. Its core technology, the MINT® (Minimally Invasive Nasal Trabeculostomy) system, represents a proprietary, stentless approach to creating drainage pathways in the trabecular meshwork during glaucoma angle surgery. The company's focus is on addressing the need for effective, low-complication glaucoma interventions. The MINT® procedure was developed to create five drainage pathways directly within the trabecular meshwork, facilitating aqueous humor outflow from the anterior chamber to Schlemm's Canal. It can be performed as a standalone procedure or combined with cataract surgery. Sanoculis has conducted clinical studies to evaluate the MINT® system. Reported two-year standalone results showed a qualified success rate of 97.2% and a complete success rate of 69.4%, based on the FDA definition of success (≥20% reduction in mean IOP without increasing glaucoma medications). Year 1 results were 92.9% qualified success and 78.6% complete success. The company continues to promote its MINT® technology as a practical approach in glaucoma surgery, emphasizing its minimally invasive nature and potential for reduced post-operative complications. As of the available information, Sanoculis remains a privately held company based in Israel.

Products and positioning

Minimally invasive, stentless glaucoma surgery solutions.

  • MINT® (Minimally Invasive Nasal Trabeculostomy)

    A stentless, minimally invasive surgical device and procedure for glaucoma. It creates five drainage pathways in the trabecular meshwork to facilitate fluid flow from the anterior chamber to Schlemm's Canal. Can be standalone or combined with cataract surgery. Uses a semi-automated trephination with a 0.14 mm cutting edge.

Sources2 sources

Cite this profile: Cite the canonical profile. /brand-wiki/sanoculis-ltd-israel · Editorial policy · How profiles are compiled